

New Peer Reviewed Publication Shows That BrainStorm's NurOwn® Has a Unique miRNA Signature

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Nov. 9, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that a study profiling NurOwn®'s unique miRNA signature has been published online in the peer-reviewed journal *Stem Cell Research & Therapy*. The publication entitled "[miRNA profiling of NurOwn®: mesenchymal stem cells secreting neurotrophic factors](#)" is authored by members of Brainstorm's scientific team.

The publication shows that NurOwn® (MSC-NTF cells) - mesenchymal stem cells (MSC) induced to secrete neurotrophic factors (NTF) - have both an enhanced secretion of NTFs as well as a distinct miRNA expression profile that distinguishes them from their MSCs of origin. miRNAs are short, non-coding RNAs that regulate gene expression by post transcriptional silencing and have been shown to play critical roles in biological processes. The study shows that BrainStorm's proprietary differentiation process modulates miRNA expression, leading to a unique miRNA signature. These findings may form the basis for the development of sensitive identity release assays for clinical trials, for *in vivo* cell identification assays and to elucidate MSC-NTF cells' mechanism of action in ALS and other neurodegenerative diseases.

"This study further confirms NurOwn's unique characteristics and underscores our leadership and scientific capability to manufacture the most advanced cell therapies to address neurodegenerative diseases," commented BrainStorm's CEO Chaim Lebovits.

About BrainStorm Cell Therapeutics Inc

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to approximately 70 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn® compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.

Safe-Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at <http://www.sec.gov>. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Contacts

Corporate:

Uri Yablonka
Chief Business Officer
BrainStorm Cell Therapeutics Inc.
Phone: 646-666-3188
uri@brainstorm-cell.com

Investors:

Michael Rice
LifeSci Advisors LLC

Phone: 646-597-6979
mrice@lifesciadvisors.com

Media:

Matt Middleman, M.D.
LifeSci Public Relations, LLC
Phone: 646-627-8384
matt@lifescipublicrelations.com

View original content with multimedia:<http://www.prnewswire.com/news-releases/new-peer-reviewed-publication-shows-that-brainstorms-nuown-has-a-unique-mirna-signature-300552722.html>

SOURCE BrainStorm Cell Therapeutics Inc.

<https://ir.brainstorm-cell.com/2017-11-09-New-Peer-Reviewed-Publication-Shows-That-BrainStorms-NurOwn-R-Has-a-Unique-miRNA-Signature>